Avalo Therapeutics, Inc. (AVTX)

Market Cap	371.86M +583.6%
Revenue (ttm)	59,000 -86.6%
Net Income	-78.26M
EPS	-5.84
Shares Out	26.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	741,933
Open	14.75
Previous Close	14.75
Day's Range	13.73 - 15.11
52-Week Range	3.39 - 20.72
Beta	0.94
Analysts	Strong Buy
Price Target	40.57 (+191.45%)
Earnings Date	May 11, 2026

About AVTX

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1β-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 15, 2015
• Employees: 33
• Stock Exchange: NASDAQ
• Ticker Symbol: AVTX
• Website: https://www.avalotx.com

Financial Performance

In 2025, Avalo Therapeutics's revenue was $59,000, a decrease of -86.62% compared to the previous year's $441,000. Losses were -$78.26 million, 122.8% more than in 2024.

Analyst Summary

According to 8 analysts, the average rating for AVTX stock is "Strong Buy." The 12-month stock price target is $40.57, which is an increase of 191.45% from the latest price.

Price Target

$40.57

(191.45% upside)

Analyst Consensus: Strong Buy